Market capitalization | $2.21b |
Enterprise Value | $2.61b |
P/E (TTM) P/E ratio | 14.46 |
EV/FCF (TTM) EV/FCF | 14.65 |
EV/Sales (TTM) EV/Sales | 3.66 |
P/S ratio (TTM) P/S ratio | 3.10 |
P/B ratio (TTM) P/B ratio | 3.11 |
Revenue growth (TTM) Revenue growth | 31.80% |
Revenue (TTM) Revenue | $712.89m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
6 Analysts have issued a Amphastar Pharmaceuticals Inc forecast:
6 Analysts have issued a Amphastar Pharmaceuticals Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 713 713 |
32%
32%
|
|
Gross Profit | 379 379 |
41%
41%
|
|
EBITDA | 285 285 |
75%
75%
|
EBIT (Operating Income) EBIT | 230 230 |
71%
71%
|
Net Profit | 167 167 |
63%
63%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
Head office | United States |
CEO | Yong Zhang |
Employees | 1,761 |
Founded | 1996 |
Website | www.amphastar.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.